Novo Nordisk A/S’s move into the cardiovascular research space is gathering pace, with successful completion of a Phase IIb study of the recently acquired anti-IL-6 ligand antibody, ziltivekimab, in atherosclerotic cardiovascular disease and inflammation. A cardiovascular outcomes trial with ziltivekimab is expected to start next year, the company reported.
The progress of ziltivekimab in the early clinical study, and the market potential of a second research program, on the use of semaglutide 2.4mg in obesity, attracted the attention of analysts during a briefing on the company’s 2020 third quarter on 30 October